SCYNEXIS Stock (NASDAQ:SCYX), Trade Ideas

SCYNEXIS

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABVC

AFMD

AREN

ATNF

BRFS

BROG

CALM

FWBI

HALL

JFBR

Kintara Therapeutics, Inc. - Common Stock

KTRA

NEXI

SCYX

Shares of  Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter.

Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Earnings

Eurozone

Commodities

Global

Intraday Update

BCLI

BPTS

MORF

RNAZ

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday.

The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to 13,243.56. The S&amp;P 500 also rose, gaining, 0.19% to 4,328.30.

Gold Moves Lower; TransCode Therapeutics Shares Surge

AGRI

ALEC

AVTX

BAER

BSFC

CALC

CANO

CFFE

CHRS

CLDI

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

EDIT

EGLX

FAZE

FFIE

KTTA

LPSN

MDBH

MIRA

MLGO

PEGY

SGBX

STSS

STTK

SWIN

TEDU

TURB

UPTD

UUUU

Gainers

TransCode Therapeutics, Inc.  (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.

Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

SCYNEXIS Inc

Cantor Fitzgerald analyst Louise Chen reiterates SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) with a Overweight.

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on SCYNEXIS

SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.20) by 95 percent. This is a 30 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $5.80 million which beat the analyst consensus estimate of $1.37 million by 323.14 percent. This is a 314.07 percent increase over sales of $1.40 million the same period last year.

Earnings Beats

Earnings Misses

SCYNEXIS Q4 EPS $(0.39) Misses $(0.20) Estimate, Sales $5.80M Beat $1.37M Estimate

<ul>
<li>In vivo&nbsp;data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis &nbsp;</li>
<li>Combination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies</li>
</ul>
&nbsp;

Biotech

General

SCYNEXIS Presented Preclinical Data On Second Generation Fungerp SCY-247 Against Mucormycosis At 11th Advances Against Aspergillosis and Mucormycosis Conference

<h3>What is a Value Stock?</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>Below is a list of notable value stocks in the healthcare sector:</h2>
<ol>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) - P/E: 0.07</li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) - P/E: 2.62</li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) - P/E: 1.26</li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) - P/E: 8.08</li>
<li>Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) - P/E: 7.34</li>
</ol>
CalciMedica's earnings per share for Q3 sits at $-0.82, whereas in Q2, they were at -1.11. Quoin Pharmaceuticals's earnings per share for Q3 sits at $-1.95, whereas in Q2, they were at -2.13. This quarter, SCYNEXIS experienced a decrease in earnings per share, which was $2.46 in Q2 and is now $-0.04. Syros Pharmaceuticals has reported Q3 earnings per share at $-1.43, which has decreased by 10.0% compared to Q2, which was -1.3. Most recently, Organon reported earnings per share at $0.87, whereas in Q2 earnings per share sat at $1.31. Most recently, the company reported a dividend yield of 7.65%, which has increased by 2.51% from last quarter's yield of 5.14%.
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

QNRX

SYRS

5 Value Stocks To Watch In The Healthcare Sector

<h3>What is a Value Stock?</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:</h2>
<ol>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) - P/E: 0.33</li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) - P/E: 7.63</li>
<li>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) - P/E: 0.96</li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) - P/E: 1.27</li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) - P/E: 1.85</li>
</ol>
Exicure saw an increase in earnings per share from -0.7 in Q1 to $-0.68 now. Voyager Therapeutics saw a decrease in earnings per share from -0.51 in Q2 to $-0.59 now. MEI Pharma's earnings per share for Q1 sits at $8.46, whereas in Q4, they were at -1.51. Most recently, SCYNEXIS reported earnings per share at $-0.04, whereas in Q2 earnings per share sat at $2.46. Most recently, Community Health Sys reported earnings per share at $-0.33, whereas in Q2 earnings per share sat at $-0.22. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

MEIP

VYGR

XCUR

A Look Into Healthcare Sector Value Stocks

SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024. &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3">Poster Presentation:</td>
</tr>
<tr>
<td>Title:</td>
<td>SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Presenting author:</td>
<td>Dr. Ashraf Ibrahim, PhD, FAAM, FECCM (Professor of Medicine, Division of Infectious Disease, David Geffen School of Medicine UCLA)</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
In this preclinical study, SCY-247 demonstrated in vivo efficacy equivalent to currently used antifungals in treating a Mucorales pulmonary infection in immunosuppressed mice. Notably, the combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement when compared to monotherapy. &nbsp;
"The results from this preclinical study are very encouraging and illustrate the significant potential for this novel fungerp candidate SCY-247," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. "Groundbreaking treatment options are urgently needed to address the significant limitations in effective therapies for devastating and very often lethal fungal diseases such as mucormycosis. We continue to expeditiously progress the development of this promising antifungal with plans to begin a clinical study by year end."
For more information, see the AAAM website <a href="https://www.globenewswire.com/Tracker?data=giSEYPCM8GJWE9QLiiAdhVUUoN4gnj0Rzq6GwpbbW_qc1Eyr7G22z4hF1ko1hnat6cSo8cYXGcpfnbyXY5q-Vg==">here</a>.
The study was funded by the National Institutes of Health (NIH) under NIH Task order A65 75N93022F00001 utilizing the National Institute of Allergy and Infectious Diseases (NIAID) suite of preclinical services for&nbsp;in vivo&nbsp;testing.
About SCY-247
SCY-247 is a second generation antifungal compound, from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), under development as therapeutic options for systemic fungal diseases. The triterpenoid class of antifungals represents the first new class of antifungal compounds since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. SCY-247 is in pre-IND development stage and has demonstrated broad-spectrum antifungal activity, in vitro and in vivo. SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for the IV and oral formulations of SCY-247.

Events

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Advances Against Aspergillosis And Mucormycosis Conference, January 25 – 27, in Milan, Italy

Shares of Resources Connection, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgp#NASDAQ">RGP</a>) rose sharply in pre-market trading following better-than-expected results for its second quarter.
Resources Connection posted quarterly adjusted earnings of 28 cents per share, beating market estimates of 18 cents per share. The company&rsquo;s quarterly sales came in at $163.1 million versus expectations of $161.936 million.
Resources Connection shares jumped 6.5% to $14.58 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Jeffs&#39; Brands Ltd(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfbr#NASDAQ">JFBR</a>) gained 60.6% to $5.06 in pre-market trading after surging 25% on Wednesday. Jeffs&#39; Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) rose 41% to $0.1984 in pre-market trading after falling over 11% on Wednesday. Kintara Therapeutics, last month, announced a review of strategic alternatives focused on maximizing stockholder value.</li>
<li>The Arena Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aren#NYSE">AREN</a>) shares rose 26.8% to $2.65 in pre-market trading after falling over 9% on Wednesday. Arena Group Board, last month, terminated employment of CEO Ross Levinsohn.</li>
<li>180 Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atnf#NASDAQ">ATNF</a>) shares gained 24.4% to $0.2550 in pre-market trading. 180 Life Sciences, last month, engaged financial advisor to explore strategic alternatives.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adn#NASDAQ">ADN</a>) shares climbed 10.2% to $0.2259 in pre-market trading after falling over 6% on Wednesday. Advent Technologies recently announced a $2 million registered direct offering of common stock.</li>
<li>BRF S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brfs#NYSE">BRFS</a>) shares rose 9.8% to $2.80 in pre-market trading. JP Morgan analyst Lucas Ferreira, last month, downgraded BRF from Overweight to Neutral.</li>
<li>Affimed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afmd#NASDAQ">AFMD</a>) shares gained 9.3% to $0.6426 in pre-market trading after declining 6% on Wednesday. Affimed announced sale of wholly-owned subsidiary AbCheck for $6 million.</li>
<li>SCYNEXIS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scyx#NASDAQ">SCYX</a>) gained 8.7% to $2.13 in pre-market trading after falling 11% on Wednesday.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) gained 8.4% to $4.01 in pre-market trading after falling 8% on Wednesday. Brooge Energy recently reached a settlement with the SEC where it agreed to pay a $5 million penalty and cease any future violations.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>SELLAS Life Sciences Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sls#NASDAQ">SLS</a>) shares fell 26.3% to $0.6674 in pre-market trading after announcing a proposed public offering.</li>
<li>Hallmark Financial Services, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hall#NASDAQ">HALL</a>) shares fell 20.5% to $0.74 in pre-market trading after declining around 25% on Wednesday. Hallmark Financial Services, on Dec. 26, announced that it intends to voluntary delist from the Nasdaq.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) shares fell 15.3% to $4.62 in pre-market trading. First Wave BioPharma shares jumped 43% on Wednesday after Roth MKM maintained a Buy rating on the stock and adjusted its target from $11 to $40.</li>
<li>ABVC BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abvc#NASDAQ">ABVC</a>) shares fell 15.1% to $1.64 in pre-market trading. ABVC BioPharma shares jumped over 60% on Wednesday after the company and its subsidiary received a milestone payment of 46 million shares from AiBtl BioPharma under a global licensing payment.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ejh#NASDAQ">EJH</a>) shares fell 14.8% to $1.26 in pre-market trading after dipping 61% on Wednesday.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) shares fell 13.8% to $1.56 in pre-market trading after surging over 86% on Wednesday.</li>
<li>Evotec SE (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evo#NASDAQ">EVO</a>) shares fell 11.4% to $9.37 in pre-market trading. Evotec and Owkin announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) shares fell 10.4% to $0.2631 in pre-market trading after dipping around 35% on Wednesday.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) fell 8.9% to $5.65 in pre-market trading after jumping around 153% on Wednesday.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) fell 5.3% to $51.94 in pre-market trading after the company reported downbeat results for its second quarter.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36484761/walgreens-conagra-brands-and-3-stocks-to-watch-heading-into-thursday"> Walgreens, Conagra Brands And 3 Stocks To Watch Heading Into Thursday</a>

<h3>Gainers</h3>
<ul>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) stock increased by 84.4% to $4.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) shares moved upwards by 75.0% to $2.1. The company's market cap stands at $16.2 million. </li>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) shares increased by 46.07% to $5.58. The market value of their outstanding shares is at $3.7 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock rose 45.4% to $18.99. The company's market cap stands at $1.1 billion. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) shares increased by 19.04% to $1.25. The company's market cap stands at $98.3 million. </li>
<li>Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) shares moved upwards by 18.26% to $27.0. The market value of their outstanding shares is at $1.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nemaura Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRD#NASDAQ">NMRD</a>) shares declined by 20.8% to $0.15 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) stock declined by 18.5% to $2.38. The market value of their outstanding shares is at $270.6 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock decreased by 9.65% to $1.3. The market value of their outstanding shares is at $46.1 million. </li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) stock decreased by 8.6% to $2.02. The market value of their outstanding shares is at $75.1 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock declined by 8.13% to $1.47. The market value of their outstanding shares is at $1.1 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock declined by 7.8% to $0.46. The market value of their outstanding shares is at $39.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGIO

ESPR

NMRD

NRXP

SNES

VNRX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) shares increased by 40.8% to $5.38 during Tuesday's after-market session. The company's market cap stands at $3.6 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock rose 7.72% to $4.46. The company's market cap stands at $2.3 million. </li>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) stock moved upwards by 6.48% to $1.15. The market value of their outstanding shares is at $3.9 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares rose 6.4% to $0.68. The market value of their outstanding shares is at $24.3 million. </li>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) shares increased by 5.97% to $1.95. The market value of their outstanding shares is at $4.8 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock moved upwards by 5.24% to $3.15. The market value of their outstanding shares is at $19.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares decreased by 12.6% to $0.47 during Tuesday's after-market session. The company's market cap stands at $16.4 million. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) stock fell 6.42% to $0.6. The company's market cap stands at $7.2 million. </li>
<li>Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) shares decreased by 5.72% to $0.62. The market value of their outstanding shares is at $159.0 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares declined by 5.67% to $1.5. The company's market cap stands at $12.6 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares decreased by 4.99% to $0.19. The market value of their outstanding shares is at $4.2 million. </li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) stock decreased by 4.98% to $2.1. The market value of their outstanding shares is at $78.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGRX

BBLG

BFRG

BIOL

NDRA

OCGN

ONCO

SIEN

SSKN

12 Health Care Stocks Moving In Tuesday's After-Market Session

-SEC Filing&nbsp;Granted for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the "GSK Territory"). The terms of the License Agreement are further
-SEC Filing
&nbsp;
Granted for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the "GSK Territory"). The terms of the License Agreement are further described in SCYNEXIS's Form 8-K dated March 30, 2023.

Contracts

SCYNEXIS Entered Into Binding MoU For Amendment To License Agreement Between Co And GSK; Granted GSK Royalty-Bearing, License For Development, Manufacture, And Commercialization Of Ibrexafungerp, Including The Approved Product BREXAFEMME

SCYNEXIS Q3 EPS $(0.04) Vs $(0.62) Last Year, Sales $1.76M vs $1.56M Last Year

The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve University, in an oral presentation titled, "SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against a Broad-spectrum of Fungal Pathogens, and Dose-dependent Tissue Distribution In Vivo" at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens Greece October 20-23, 2023. &nbsp;

SCYNEXIS Presents New Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Congress On Trends In Medical Mycology

SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023. &nbsp;
Oral Presentation:
Title: SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against Broad-spectrum of Fungal Pathogens, and Dose-Dependent Tissue Distribution In Vivo
Session: Symposium 8: Clinic meets Pharmacology: Antifungal treatment Abstract number: S08.6 Date: Saturday, October 21 Time: 3:35 p.m EEST / 8:35 a.m. EDT Presenting author: Mahmoud Ghannoum, Ph.D. (Ohio, United States)
Location: Room MC3, Megaron Athens International Conference Center
For more information, see the TIMM website <a href="https://www.globenewswire.com/Tracker?data=5RDArZCeNFvcMqApI50IRgoakSWFpic9ygk5XhS1eb_LswY5gNe6L7EZEzpQ-_YN6QxONpdl9my5IOXXSsC7_g==">here</a>.
About SCY-247
SCY-247 is a second-generation antifungal compound from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), under development as a therapeutic option for systemic fungal diseases. The fungerps represent the first new class of antifungal compounds since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility for oral and intravenous (IV) routes of administration. SCY-247 has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, and SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for its IV and oral formulations. SCYNEXIS plans to begin clinical studies in the second half of 2024.

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Congress On Trends In Medical Mycology October 20-23 In Athens, Greece

SCYNEXIS Recalls BREXAFEMME Nationwide Over Potential Cross Contamination With A Non-Antibacterial ß-Lactam Drug Substance

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday.
The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to 13,243.56. The S&amp;P 500 also rose, gaining, 0.19% to 4,328.30.
Check This Out: <a href="https://www.benzinga.com/news/23/09/34861974/baidu-to-rally-over-29-here-are-10-other-analyst-forecasts-for-monday"> Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday</a>
&nbsp; 
<h3>Leading and Lagging Sectors</h3>

Energy shares rose by 1.2% on Monday.
In trading on Monday, consumer staples shares fell by 0.7%.
&nbsp; 
<h3>Top Headline</h3>

The Chicago Fed National Activity Index declined to -0.16 in August versus a revised reading of 0.07 in July.
&nbsp; 
<h3>Equities Trading UP</h3>

TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares shot up 218% to $2.11 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Shares of ESS Tech, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gwh#NYSE">GWH</a>) got a boost, shooting 24% to $1.7173. Honeywell International Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hon#NASDAQ">HON</a>) entered into a strategic collaboration with ESS Tech to advance technology development and market adoption of iron flow battery (IFB) energy storage systems.
Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) shares were also up, gaining 54% to $1.4199 after the company and Skyepharma announced the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.
&nbsp; 
<h3>Equities Trading DOWN</h3>

SCYNEXIS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scyx#NASDAQ">SCYX</a>) shares dropped 34% to $2.17 after the company announced it is recalling BREXAFEMME and temporarily halting clinical studies of ibrexafungerp due to the risk of cross contamination with a non-bacterial beta-lactam drug substance during the manufacturing process.
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcli#NASDAQ">BCLI</a>) were down 33% to $0.55 after the FDA said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company&#39;s ALS therapy is reasonably likely to predict clinical benefit.
Morphic Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/morf#NASDAQ">MORF</a>) was down, falling 37% to $23.19 after BTIG downgraded the stock from Buy to Neutral.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34864602/vivani-medical-and-2-other-stocks-under-2-insiders-are-buying"> Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying </a>
&nbsp; 
<h3>Commodities</h3>

In commodity news, oil traded down 0.4% to $89.68 while gold traded down 0.5% at $1,936.20.
Silver traded down 2% to $23.37 on Monday while copper fell 0.7% to $3.6705.
&nbsp; 
<h3>Euro zone</h3>

European shares closed lower today. The eurozone&rsquo;s STOXX 600 fell 0.62% London&rsquo;s FTSE 100 fell 0.78% while Spain&rsquo;s IBEX 35 Index fell 1.22% The German DAX fell 0.98% French CAC 40 declined 0.85%, while Italy&rsquo;s FTSE MIB Index dipped 0.68%.
The Ifo Business Climate indicator for Germany fell to 85.7 in September from August&#39;s revised reading of 85.8. Producer prices in Spain fell 10% year-over-year in August versus a revised 8.6% decline in the previous month.
&nbsp; 
<h3>Asia Pacific Markets</h3>

Asian markets closed mixed on Monday, with Japan&rsquo;s Nikkei 225 gaining 0.85%, Hong Kong&rsquo;s Hang Seng Index falling 1.82% and China&rsquo;s Shanghai Composite Index declining 0.54%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, gained 0.1%.
&nbsp; 
<h3>Economics</h3>

The Chicago Fed National Activity Index declined to -0.16 in August versus a revised reading of 0.07 in July.
The Federal Reserve Bank of Dallas&rsquo; general business activity index for manufacturing in Texas declined to -18.1 in September from -17.2 a month ago.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34861977/top-4-tech-stocks-that-may-explode-in-q3"> Top 4 Tech Stocks That May Explode In Q3</a>
&nbsp; 
<h3>COVID-19 Update</h3>

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,590,470 cases with around 1,176,090 deaths. India confirmed a total of at least 44,998,520 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 695,729,180 cases of COVID-19 worldwide with more than 6,919,340 deaths.

<h3>Gainers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares rose 219.3% to $2.12 during Monday's regular session. TransCode Therapeutics's stock is trading at a volume of 72.3 million shares as of 13:30 EST. This is 12088.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.2 million. </li>
<li>Vaccitech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VACC#NASDAQ">VACC</a>) shares increased by 82.73% to $3.07. Trading volume for Vaccitech's stock is 18.2 million as of 13:30 EST. This is 135511.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $118.2 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) shares moved upwards by 71.57% to $1.51. As of 13:30 EST, this security is trading at a volume of 60.8 million shares, making up 13632.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.1 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock rose 25.08% to $0.15. As of 13:30 EST, this security is trading at a volume of 274.7 million shares, making up 818.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.0 million. </li>
<li>Cano Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANO#NYSE">CANO</a>) shares rose 20.05% to $0.27. As of 13:30 EST, Cano Health's stock is trading at a volume of 13.1 million, which is 119.8% of its average full-day volume over the last 100 days. The company's market cap stands at $77.5 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares moved upwards by 18.77% to $5.44. Trading volume for Bluejay Diagnostics's stock is 343.4K as of 13:30 EST. This is 28.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock decreased by 38.7% to $0.5 during Monday's regular session. Trading volume for Brainstorm Cell's stock is 2.2 million as of 13:30 EST. This is 796.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.5 million. </li>
<li>Morphic Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>) stock decreased by 32.67% to $24.7. The current volume of 4.7 million shares is 1024.0% of Morphic Holding's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.1 billion. </li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) stock decreased by 32.03% to $2.25. Trading volume for this security as of 13:30 EST is 3.1 million, which is 962.3% of its average full-day volume over the last 100 days. The company's market cap stands at $83.6 million. </li>
<li>Axcella Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXLA#NASDAQ">AXLA</a>) shares declined by 16.62% to $8.63. The current volume of 182.7K shares is 22.4% of Axcella Health's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $25.4 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock decreased by 15.52% to $0.2. Trading volume for this security as of 13:30 EST is 38.8 million, which is 128.2% of its average full-day volume over the last 100 days. The company's market cap stands at $66.6 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares decreased by 12.6% to $0.22. As of 13:30 EST, T2 Biosystems's stock is trading at a volume of 49.6 million, which is 43.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $74.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXLA

BJDX

LIFW

TTOO

VACC

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers
TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) gained 46.9% to $0.2247 after falling over 4% on Friday.
Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) shares climbed 23.5% to $0.1472 after gaining 16% on Friday. The company recently announced the sale of its assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) on Sept. 12.
Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) shares gained 22.3% to $1.1250 after the company and Skyepharma announced the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.
Cano Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cano#NYSE">CANO</a>) rose 20.5% to $0.2727.
Sharps Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stss#NASDAQ">STSS</a>) surged 18.2% to $0.6703.
CalciMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calc#NASDAQ">CALC</a>) climbed 16.3% to $3.0699.
TradeUP Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uptd#NASDAQ">UPTD</a>) gained 14% to $14.50
So-Young International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sy#NASDAQ">SY</a>) gained 13.5% to $1.2263.
Shattuck Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sttk#NASDAQ">STTK</a>) rose 13.3% to $1.71.
Pasithea Therapeutics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktta#NASDAQ">KTTA</a>) gained 13.1% to $0.4998.
Enthusiast Gaming Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eglx#NASDAQ">EGLX</a>) gained 12.7% to $0.3367.
InnSuites Hospitality Trust (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iht#NYSE">IHT</a>) surged 12.5% to $1.4399.
Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) rose 12.5% to $0.9422.
ESS Tech, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gwh#NYSE">GWH</a>) shares climbed 10.1% to $1.53. Honeywell International Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hon#NASDAQ">HON</a>) entered into a strategic collaboration with ESS Tech to advance technology development and market adoption of iron flow battery (IFB) energy storage systems.
Solo Brands, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dtc#NYSE">DTC</a>) gained 10% to $4.9605. Craig-Hallum initiated coverage on Solo Brands with a Buy rating and announced a price target of $8.
Sea Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/se#NYSE">SE</a>) surged 9.7% to $39.46.
MDB Capital Holdings, LLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdbh#NASDAQ">MDBH</a>) gained 9.5% to $11.51.
Williams-Sonoma, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wsm#NYSE">WSM</a>) surged 8.9% to $152.52 after a 13G filing showed Green Equity Investors IX, L.P. increased its stake in the company to 5%.
Bridger Aerospace Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/baer#NASDAQ">BAER</a>) rose 8.8% to $8.40.
MIRA Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mira#NASDAQ">MIRA</a>) shares surged 7.5% to $5.02 after gaining 4% on Friday.
Energy Fuels Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uuuu#NASDAQ">UUUU</a>) gained 5.6% to $8.66.
Losers
SCYNEXIS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scyx#NASDAQ">SCYX</a>) shares declined 35.9% to $1.9350 after the company announced it is recalling BREXAFEMME and temporarily halting clinical studies of ibrexafungerp due to the risk of cross contamination with a non-bacterial beta-lactam drug substance during the manufacturing process.
MicroAlgo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlgo#NASDAQ">MLGO</a>) fell 34.5% to $3.13. MicroAlgo shares jumped 110% on Friday after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
Turbo Energy, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/turb#NASDAQ">TURB</a>) fell 33.1% to $3.35. Turbo Energy reported pricing of IPO at $5.00 per ADS.
Brainstorm Cell Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcli#NASDAQ">BCLI</a>) fell 32.6% to $0.5498 after the FDA said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company&#39;s ALS therapy is reasonably likely to predict clinical benefit.
Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) declined 23.2% to $ 3.1117.
Rite Aid Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rad#NYSE">RAD</a>) shares fell 22% to $0.4601. Rite Aid is looking to close hundreds of stores in bankruptcy, the Wall Street Journal reported.
Safe &amp; Green Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgbx#NASDAQ">SGBX</a>) shares fell 21.3% to $1.1095 after dipping 22% on Friday.
Blue Star Foods Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsfc#NASDAQ">BSFC</a>) declined 19.4% to $0.2333.
GSE Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gvp#NASDAQ">GVP</a>) fell 17.7% to $0.2468.
Morphic Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/morf#NASDAQ">MORF</a>) declined 17.4% to $30.25 after BTIG downgraded the stock from Buy to Neutral.
Solowin Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swin#NASDAQ">SWIN</a>) fell 16.5% to $3.09 after declining around 9% on Friday.
Pineapple Energy Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pegy#NASDAQ">PEGY</a>) declined 15.4% to $0.8134.
Faraday Future Intelligent Electric Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ffie#NASDAQ">FFIE</a>) fell 15% to $3.33.
AgriFORCE Growing Systems Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) declined 14.6% to $0.1123.
Alector, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alec#NASDAQ">ALEC</a>) fell 14.4% to $5.89 after Goldman Sachs initiated coverage on the stock with a Sell rating and $4 price target.
Connexa Sports Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxa#NASDAQ">CNXA</a>) dropped 13.8% to $4.5499 after the company announced that it received a letter from the Nasdaq regarding the late filing of its quarterly report.
CF Acquisition Corp. VIII (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cffe#NASDAQ">CFFE</a>) fell 12.2% to $14.35 after gaining 13% on Friday.
Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) fell 8.6% to $35.87.
Tarena International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tedu#NASDAQ">TEDU</a>) fell 8.5% to $1.9201.
VinFast Auto Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vfs#NASDAQ">VFS</a>) fell 8.5% to $14.25.
LivePerson, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpsn#NASDAQ">LPSN</a>) fell 8.3% to $4.06.
Editas Medicine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edit#NASDAQ">EDIT</a>) dipped 8.2% to $7.21.
Coherus BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) fell 6.8% to $4.1550. Coherus BioSciences announced the FDA issued a complete response letter for UDENYCA ONBODY biologics license application solely due to an ongoing review of inspection findings at a third-party filler.
Hawaiian Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ha#NASDAQ">HA</a>) declined 6.6% to $6.37. Hawaiian Holdings sees third-quarter ASMs up 4.0% to up 5.5%.
Alcoa Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aa#NYSE">AA</a>) fell 6.2% to $26.58. Alcoa disclosed the appointment of William F. Oplinger as President and Chief Executive Officer and as a member of its Board of Directors, effective September 24, 2023.
Now Read This: <a href="https://www.benzinga.com/news/23/09/34861974/baidu-to-rally-over-29-here-are-10-other-analyst-forecasts-for-monday"> Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday</a>

Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite trading higher on Monday.
The Dow traded down 0.01% to 33,962.53 while the NASDAQ rose 0.26% to 13,246.15. The S&amp;P 500 also rose, gaining, 0.22% to 4,329.75.
Check This Out: <a href="https://www.benzinga.com/news/23/09/34861974/baidu-to-rally-over-29-here-are-10-other-analyst-forecasts-for-monday"> Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday</a>
&nbsp; 
<h3>Leading and Lagging Sectors</h3>

Energy shares rose by 1.1% on Monday.
In trading on Monday, utilities shares fell by 0.8%.
&nbsp; 
<h3>Top Headline</h3>

The Chicago Fed National Activity Index declined to -0.16 in August versus a revised reading of 0.07 in July.
&nbsp; 
<h3>Equities Trading UP</h3>

TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares shot up 242% to $2.27 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Shares of ESS Tech, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gwh#NYSE">GWH</a>) got a boost, shooting 17% to $1.6196. Honeywell International Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hon#NASDAQ">HON</a>) entered into a strategic collaboration with ESS Tech to advance technology development and market adoption of iron flow battery (IFB) energy storage systems.
Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) shares were also up, gaining 67% to $1.5393 after the company and Skyepharma announced the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.
&nbsp; 
<h3>Equities Trading DOWN</h3>

SCYNEXIS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scyx#NASDAQ">SCYX</a>) shares dropped 32% to $2.2429 after the company announced it is recalling BREXAFEMME and temporarily halting clinical studies of ibrexafungerp due to the risk of cross contamination with a non-bacterial beta-lactam drug substance during the manufacturing process.
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcli#NASDAQ">BCLI</a>) were down 40% to $0.4910 after the FDA said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company&#39;s ALS therapy is reasonably likely to predict clinical benefit.
Morphic Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/morf#NASDAQ">MORF</a>) was down, falling 21% to $28.82 after BTIG downgraded the stock from Buy to Neutral.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34864602/vivani-medical-and-2-other-stocks-under-2-insiders-are-buying"> Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying</a>
&nbsp; 
<h3>Commodities</h3>

In commodity news, oil traded down 0.8% to $89.35 while gold traded down 0.5% at $1,936.50.
Silver traded down 2.1% to $23.335 on Monday while copper fell 0.8% to $3.6655.
&nbsp; 
<h3>Euro zone</h3>

European shares were lower today. The eurozone&rsquo;s STOXX 600 fell 0.93% London&rsquo;s FTSE 100 fell 1.17% while Spain&rsquo;s IBEX 35 Index fell 1.53% The German DAX fell 1.31% French CAC 40 declined 1.19%, while Italy&rsquo;s FTSE MIB Index dipped 1.21%.
The Ifo Business Climate indicator for Germany fell to 85.7 in September from August&#39;s revised reading of 85.8. Producer prices in Spain fell 10% year-over-year in August versus a revised 8.6% decline in the previous month.
&nbsp; 
<h3>Asia Pacific Markets</h3>

Asian markets closed mixed on Monday, with Japan&rsquo;s Nikkei 225 gaining 0.85%, Hong Kong&rsquo;s Hang Seng Index falling 1.82% and China&rsquo;s Shanghai Composite Index declining 0.54%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, gained 0.1%.
&nbsp; 
<h3>Economics</h3>

The Chicago Fed National Activity Index declined to -0.16 in August versus a revised reading of 0.07 in July.
The Federal Reserve Bank of Dallas&rsquo; general business activity index for manufacturing in Texas declined to -18.1 in September from -17.2 a month ago.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34861977/top-4-tech-stocks-that-may-explode-in-q3"> Top 4 Tech Stocks That May Explode In Q3</a>
&nbsp; 
<h3>COVID-19 Update</h3>

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,590,470 cases with around 1,176,090 deaths. India confirmed a total of at least 44,998,520 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 695,729,180 cases of COVID-19 worldwide with more than 6,919,340 deaths.

Nasdaq Turns Higher; SCYNEXIS Shares Plunge

Scynexis Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scyx#NASDAQ">SCYX</a>) is voluntarily&nbsp;<a class="editor-rtfLink" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1178253/000095017023049544/scyx-20230919.htm" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">recalling</a>&nbsp;its antifungal pill, Brexafemme (ibrexafungerp), from the market and placing a temporary hold on clinical studies of ibrexafungerp, including the Phase 3 MARIO study, until a mitigation strategy and a resupply plan are determined.
The yeast infection pill was&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/06/21386295/scynexis-scores-fda-nod-for-brexafemme-oral-treatment-for-vaginal-yeast-infection" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">first approved in 2021</a>.
The move follows the risk of cross-contamination with a potential allergy-inducing compound.
The FDA approved Brexafemme for vulvovaginal candidiasis (VVC) and reduced the incidence of recurrent VVC (RVVC).&nbsp;
Scynexis became aware that a non-antibacterial beta-lactam drug substance is manufactured using equipment common to the manufacturing process for ibrexafungerp.
Current FDA guidance recommends segregating the manufacture of beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction.
In March this year,&nbsp;GSK plc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gsk#NYSE">GSK</a>) and Scynexis entered an exclusive license agreement for Brexafemme for an upfront payment&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/03/31583851/gsk-bets-on-scynexis-fda-approved-antifungal-drug-for-over-500m-in-bio-bucks" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">of $90 million</a>.
Price Action:&nbsp;SCYX shares are down 34.40% at $2.17 on the last check Monday.

Large Cap

Health Care

Why Are Antifungal Focused Scynexis Stock Plunging Today?

U.S. stocks traded mostly lower this morning, with the Dow Jones trading falling around 80 points on Monday.
Following the market opening Monday, the Dow traded down 0.26% to 33,875.83 while the NASDAQ fell 0.05% to 13,205.29. The S&amp;P 500 also fell, dropping, 0.13% to 4,314.62.
Check This Out: <a href="https://www.benzinga.com/news/23/09/34788367/mcdonalds-halliburton-and-2-other-stocks-insiders-are-selling"> McDonald&#39;s, Halliburton And 2 Other Stocks Insiders Are Selling</a>
&nbsp; 
<h3>Leading and Lagging Sectors</h3>

Energy shares rose by 0.2% on Monday.
In trading on Monday, utilities shares fell by 0.8%.
&nbsp; 
<h3>Top Headline</h3>

The Chicago Fed National Activity Index declined to -0.16 in August versus a revised reading of 0.07 in July.
&nbsp; 
<h3>Equities Trading UP</h3>

TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares shot up 165% to $1.76 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Shares of FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) got a boost, shooting 50% to $0.2289 after falling over 4% on Friday.
Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) shares were also up, gaining 20% to $1.10 after the company and Skyepharma announced the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.
&nbsp; 
<h3>Equities Trading DOWN</h3>

SCYNEXIS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scyx#NASDAQ">SCYX</a>) shares dropped 43% to $1.89 after the company announced it is recalling BREXAFEMME and temporarily halting clinical studies of ibrexafungerp due to the risk of cross contamination with a non-bacterial beta-lactam drug substance during the manufacturing process.
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcli#NASDAQ">BCLI</a>) were down 41% to $0.4790 after the FDA said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company&#39;s ALS therapy is reasonably likely to predict clinical benefit.
MicroAlgo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlgo#NASDAQ">MLGO</a>) was down, falling 35% to $3.1007. MicroAlgo shares jumped 110% on Friday after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
Also Check This Out:<a href="https://www.benzinga.com/news/23/09/34789113/top-4-health-care-stocks-that-should-keep-you-up-at-night"> Top 4 Health Care Stocks That Should Keep You Up At Night </a>
&nbsp; 
<h3>Commodities</h3>

In commodity news, oil traded down 0.1% to $89.93 while gold traded down 0.1% at $1,944.10.
Silver traded down 0.1% to $23.825 on Monday while copper fell 0.5% to $3.6780.
&nbsp; 
<h3>Euro zone</h3>

European shares were lower today. The eurozone&rsquo;s STOXX 600 fell 0.7% London&rsquo;s FTSE 100 fell 0.7% while Spain&rsquo;s IBEX 35 Index fell 0.9% The German DAX fell 0.8% French CAC 40 declined 0.7%, while Italy&rsquo;s FTSE MIB Index dipped 0.8%.
The Ifo Business Climate indicator for Germany fell to 85.7 in September from August&#39;s revised reading of 85.8. Producer prices in Spain fell 10% year-over-year in August versus a revised 8.6% decline in the previous month.
&nbsp; 
<h3>Asia Pacific Markets</h3>

Asian markets closed mixed on Monday, with Japan&rsquo;s Nikkei 225 gaining 0.85%, Hong Kong&rsquo;s Hang Seng Index falling 1.82% and China&rsquo;s Shanghai Composite Index declining 0.54%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, gained 0.1%.
&nbsp; 
<h3>Economics</h3>

The Chicago Fed National Activity Index declined to -0.16 in August versus a revised reading of 0.07 in July.
&nbsp; 
<h3>COVID-19 Update</h3>

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,590,470 cases with around 1,176,090 deaths. India confirmed a total of at least 44,998,520 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 695,729,180 cases of COVID-19 worldwide with more than 6,919,340 deaths.

U.S. Stocks Open Lower; Chicago Fed Index Falls In August

FLEX, PNST and CAN among pre-market losers

GSK revises Scynexis licensing deal for antifungal agent

A rating of 81 puts SCYNEXIS Inc (SCYX) near the top of the Drug Manufacturers - Specialty and Generic industry according to InvestorsObserver. SCYNEXIS Inc's score of 81 means it scores higher than 81% of stocks in the industry. SCYNEXIS Inc also received an overall rating of 49, putting it above 49% of all stocks. Drug M

Where Does SCYNEXIS Inc (SCYX) Stock Fall in the Drug Manufacturers - Specialty & Generic Field After It Is Down 0.00% This Week?

SCYNEXIS Inc (SCYX) has risen Thursday morning, with the stock increasing 1.53% in pre-market trading to 1.99. SCYX's short-term technical score of 48 indicates that the stock has traded less bullishly over the last month than 52% of stocks on the market. In the Drug Manufacturers - Specialty and Generic industry, which ra

Should You Buy SCYNEXIS Inc (SCYX) Stock Thursday Morning?

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on SCYNEXIS (SCYX – Research Report) today and set a price target of $7.50...

Promising Antifungal Drug Developments Bolster Buy Rating for SCYNEXIS

SCYNEXIS GAAP EPS of $1.39 misses by $0.14, revenue of $140.14M misses by $1.84M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
SCYNEXIS (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) just reported results for the fourth quarter of 2023.<ul><li>SCYNEXIS reported earnings per share of -39 cents. This was below the analyst estimate for EPS of -20 cents.</li><li>The company reported revenue of $5.80 million.</li><li>This was 323.14% better than the analyst estimate for revenue of $1.37 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/scyx-stock-earnings-scynexis-for-q4-of-2023/">SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023

Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership

Scynexis: Update Following Restructuring Of GSK Deal

SCYNEXIS (SCYX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Max...

Buy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline Prospects

ATXG

BETS

BTBT

BTDR

CLSK

FLEX

GREE

HIVE

MARA

PNST

RIOT

WULF

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

SCYX DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action – SCYX

SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Legal

SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

DEADLINE ALERT for SCYX, LICY, and FMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)